Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25071676 |
GB |
||
Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, DENOSUMAB, PREGABALIN, |
||||
| 302 | 25072042 |
US |
68 | 2 |
Malignant neoplasm progression, Inappropriate schedule of product administration, |
||||
ABEMACICLIB, |
||||
| 303 | 25072062 |
CN |
49 | 2 |
Malignant neoplasm progression, Pericardial effusion malignant, Malignant pleural effusion, Central nervous system lesion, Condition aggravated, |
||||
AFATINIB, AFATINIB, |
||||
| 304 | 25072215 |
JP |
73 | 2 |
Malignant neoplasm progression, Diarrhoea, |
||||
AFATINIB, AFATINIB, |
||||
| 305 | 25072358 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, CABAZITAXEL, PREDNISONE, SIPULEUCEL-T, ATEZOLIZUMAB, CABOZANTINIB, CARBOPLATIN, |
||||
| 306 | 25072388 |
JP |
56 | 1 |
Immune-mediated hepatitis, Malignant neoplasm progression, Product use issue, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 307 | 25072535 |
DE |
2 | |
Polyneuropathy, Neoplasm malignant, Metastases to liver, Breast cancer metastatic, Malignant neoplasm progression, Metastases to the mediastinum, Metastases to lung, Ascites, Pericardial effusion, Pleural effusion, |
||||
LETROZOLE, LETROZOLE TABLETS, CAPECITABINE, FULVESTRANT, PACLITAXEL, RIBOCICLIB, RIBOCICLIB, |
||||
| 308 | 25072710 |
PE |
51 | |
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 309 | 25073469 |
JP |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, TREMELIMUMAB, |
||||
| 310 | 25073594 |
US |
61 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 311 | 25073599 |
US |
73 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, PREDNISONE, |
||||
| 312 | 25073668 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, PREDNISONE, |
||||
| 313 | 25073908 |
GR |
1 | |
Breast cancer metastatic, Intestinal metastasis, Malignant neoplasm progression, |
||||
RIBOCICLIB, |
||||
| 314 | 25074310 |
US |
67 | 2 |
Malignant neoplasm progression, Pain, |
||||
PALBOCICLIB, |
||||
| 315 | 25074321 |
NL |
||
Pneumonitis, Malignant neoplasm progression, Peripheral sensory neuropathy, Off label use, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, PACLITAXEL, CARBOPLATIN, |
||||
| 316 | 25074364 |
ES |
70 | 1 |
Peritonitis, Chronic kidney disease, Malignant neoplasm progression, Eczema eyelids, Anal inflammation, Erythema, Dermatitis acneiform, Stomatitis, Rash, Proteinuria, Asthenia, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ALLOPURINOL, FOLIC ACID, PARICALCITOL, |
||||
| 317 | 25074595 |
US |
61 | 1 |
Malignant neoplasm progression, Drug ineffective, Drug intolerance, Toxicity to various agents, Product use in unapproved indication, |
||||
BENDAMUSTINE HCL, BENDAMUSTINE HCL, DOXORUBICIN, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BORTEZOMIB FOR INJECTION, BORTEZOMIB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, ETOPOSIDE PHOSPHATE, ETOPOSIDE PHOSPHATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, OBINUTUZUMAB, OBINUTUZUMAB, |
||||
| 318 | 25074686 |
JP |
58 | 2 |
Death, Gait inability, Eastern Cooperative Oncology Group performance status worsened, Malignant neoplasm progression, Pyrexia, Pain, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 319 | 25074746 |
JP |
||
Thrombosis, Malignant neoplasm progression, |
||||
RAMUCIRUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 320 | 25075067 |
US |
70 | |
Prostate cancer metastatic, Malignant neoplasm progression, Prostate cancer, Hydronephrosis, Metastases to lung, Calcification metastatic, Retroperitoneal lymphadenopathy, Hepatic steatosis, Lymphadenopathy, Intervertebral disc degeneration, Arthritis, Osteopenia, Pulse abnormal, Arthrodesis, Off label use, Palliative care, |
||||
CAPIVASERTIB, OLAPARIB, CABAZITAXEL, |
||||
| 321 | 25075399 |
US |
||
Malignant neoplasm progression, |
||||
AXITINIB, |
||||
| 322 | 25075842 |
IT |
83 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
BENDAMUSTINE HCL, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, |
||||
| 323 | 25075892 |
FR |
||
Pyrexia, Inflammation, Malignant neoplasm progression, Tumour necrosis, Tumour pseudoprogression, Product use in unapproved indication, |
||||
DOSTARLIMAB, DOSTARLIMAB, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, |
||||
| 324 | 25075988 |
JP |
67 | 2 |
Small intestinal perforation, Malignant neoplasm progression, Adrenal disorder, Hypothyroidism, Toxic skin eruption, |
||||
PEMBROLIZUMAB, |
||||
| 325 | 25076015 |
JP |
8 | 1 |
Rheumatoid arthritis, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 326 | 25076393 |
ES |
1 | |
Renal cell carcinoma, Malignant neoplasm progression, Metastases to lung, Metastases to retroperitoneum, Metastases to lymph nodes, Metastases to central nervous system, Renal impairment, Palmar-plantar erythrodysaesthesia syndrome, |
||||
SUNITINIB MALATE, SUNITINIB MALATE, SUNITINIB MALATE, NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 327 | 25076425 |
CH |
1 | |
Radiotherapy, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 328 | 25076450 |
US |
68 | 1 |
Papillary thyroid cancer, Metastases to bone, Malignant neoplasm progression, Product use in unapproved indication, |
||||
ZOLEDRONIC ACID, DABRAFENIB, TRAMETINIB, |
||||
| 329 | 25076523 |
US |
33 | 1 |
Malignant neoplasm progression, Drug ineffective, Product use in unapproved indication, |
||||
DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, PREDNISONE, CLADRIBINE, CYTARABINE, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, |
||||
| 330 | 25076558 |
JP |
7 | 2 |
Malignant neoplasm progression, Postrenal failure, Proteinuria, Polydipsia, Vaginal prolapse, Hypertension, Erythema, Hyponatraemia, Decreased appetite, Drug ineffective, |
||||
PEMBROLIZUMAB, |
||||
| 331 | 25076717 |
VN |
||
Malignant neoplasm progression, |
||||
AFATINIB, |
||||
| 332 | 25066326 |
JP |
75 | 1 |
Malignant neoplasm progression, Hypersomnia, Off label use, |
||||
RISPERIDONE, |
||||
| 333 | 25066629 |
US |
62 | 1 |
Malignant neoplasm progression, Abdominal pain upper, Pyrexia, |
||||
PANCRELIPASE, |
||||
| 334 | 25066738 |
CA |
33 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
DOXORUBICIN, PEMBROLIZUMAB, ABEMACICLIB, |
||||
| 335 | 25066765 |
FR |
||
Malignant neoplasm progression, Drug ineffective for unapproved indication, Intentional product use issue, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, |
||||
| 336 | 25066850 |
CA |
64 | 1 |
Death, Malignant neoplasm progression, |
||||
OXALIPLATIN, OXALIPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, CAPECITABINE, CAPECITABINE, TRASTUZUMAB, TRASTUZUMAB, |
||||
| 337 | 25067340 |
CN |
46 | |
Drug resistance, Malignant neoplasm progression, Metastases to liver, |
||||
OSIMERTINIB, |
||||
| 338 | 25067831 |
CA |
60 | 2 |
Breast cancer, Malignant neoplasm progression, |
||||
FULVESTRANT, RIBOCICLIB, |
||||
| 339 | 25068136 |
US |
2 | |
Malignant neoplasm progression, White blood cell count decreased, |
||||
PALBOCICLIB, |
||||
| 340 | 25068644 |
CN |
2 | |
Malignant neoplasm progression, |
||||
LORLATINIB, |
||||
| 341 | 25069447 |
JP |
7 | 2 |
Malignant neoplasm progression, Immune-mediated hepatic disorder, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 342 | 25069458 |
JP |
69 | 1 |
Hepatitis, Cholangitis, Malignant neoplasm progression, Blood alkaline phosphatase increased, Gamma-glutamyltransferase increased, Aspartate aminotransferase increased, Alanine aminotransferase increased, |
||||
NECITUMUMAB, GEMCITABINE HYDROCHLORIDE, CISPLATIN, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, |
||||
| 343 | 25069465 |
JP |
75 | 1 |
Malignant neoplasm progression, Compartment syndrome, Impaired healing, Lymphadenopathy, Contusion, |
||||
PIRTOBRUTINIB, |
||||
| 344 | 25069498 |
JP |
65 | 2 |
Malignant neoplasm progression, Ileus, Small intestinal perforation, Peritonitis, Enterocutaneous fistula, Abscess, |
||||
PEMBROLIZUMAB, |
||||
| 345 | 25069503 |
ZA |
||
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 346 | 25069615 |
RO |
50 | 1 |
B-cell type acute leukaemia, Malignant neoplasm progression, |
||||
TISAGENLECLEUCEL, ACYCLOVIR, FLUCONAZOLE, |
||||
| 347 | 25069728 |
CA |
||
Malignant glioma, Malignant neoplasm progression, |
||||
CISPLATIN, DABRAFENIB, TRAMETINIB, |
||||
| 348 | 25069856 |
DE |
60 | 2 |
Neuropathy peripheral, Malignant neoplasm progression, Therapy partial responder, Proteinuria, |
||||
PACLITAXEL, OXALIPLATIN, PEMBROLIZUMAB, FLUOROURACIL, FLUOROURACIL, RAMUCIRUMAB, |
||||
| 349 | 25070149 |
CN |
48 | |
Malignant neoplasm progression, Malignant transformation, Drug resistance, |
||||
GEFITINIB, GEFITINIB, GEFITINIB, |
||||
| 350 | 25070164 |
CL |
80 | 1 |
General physical health deterioration, Malignant neoplasm progression, Weight decreased, Off label use, |
||||
CETUXIMAB, |
||||
| 351 | 25070300 |
US |
2 | |
Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 352 | 25070334 |
US |
68 | 2 |
Device occlusion, Cholecystitis, Renal cancer, Malignant neoplasm progression, |
||||
AXITINIB, AXITINIB, |
||||
| 353 | 25070361 |
PL |
61 | 2 |
Malignant neoplasm progression, Hyperthyroidism, Immune-mediated hepatic disorder, |
||||
PACLITAXEL, NIVOLUMAB, IPILIMUMAB, CARBOPLATIN, |
||||
| 354 | 25070373 |
US |
39 | 2 |
Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 355 | 25070393 |
KR |
30 | 1 |
Diffuse large B-cell lymphoma, Malignant neoplasm progression, Cytokine release syndrome, |
||||
TISAGENLECLEUCEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE, |
||||
| 356 | 25070956 |
BG |
40 | 2 |
Malignant neoplasm progression, Metastases to bone, Breast cancer metastatic, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, EPIRUBICIN HYDROCHLORIDE, FLUOROURACIL, |
||||
| 357 | 25070977 |
RU |
60 | 2 |
Malignant neoplasm progression, Dizziness, Speech disorder, Aphasia, Confusional state, |
||||
CRIZOTINIB, |
||||
| 358 | 25071227 |
US |
57 | |
Malignant neoplasm progression, |
||||
TIVOZANIB, CABOZANTINIB, AXITINIB, |
||||
| 359 | 25071556 |
JP |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 360 | 25062326 |
JP |
68 | 2 |
Malignant neoplasm progression, Thrombocytopenia, Haemoglobin decreased, White blood cell count decreased, |
||||
PEMBROLIZUMAB, |
||||
| 361 | 25062474 |
HU |
2 | |
Breast cancer, Malignant neoplasm progression, Metastases to bone, Metastases to ovary, Renal impairment, Metastases to uterus, Vertebral lesion, Rash, Erythema, Skin exfoliation, Tumour marker increased, Bone lesion, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, FULVESTRANT, |
||||
| 362 | 25062605 |
BG |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 363 | 25062791 |
CA |
||
Malignant neoplasm progression, Metastases to central nervous system, |
||||
OLAPARIB, |
||||
| 364 | 25062914 |
US |
||
Colorectal cancer metastatic, Malignant neoplasm progression, |
||||
OXALIPLATIN, FLUOROURACIL, |
||||
| 365 | 25062944 |
JP |
55 | 1 |
Metastatic renal cell carcinoma, Malignant neoplasm progression, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, DASATINIB, DASATINIB, CABOZANTINIB, NIVOLUMAB, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, MIGLITOL, AZILSARTAN KAMEDOXOMIL, AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, |
||||
| 366 | 25063225 |
CA |
2 | |
Colon cancer, Hydronephrosis, Malignant neoplasm progression, Off label use, Ovarian cancer, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 367 | 25063318 |
JP |
62 | 1 |
Pulmonary embolism, Metastasis, Malignant neoplasm progression, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, |
||||
| 368 | 25063445 |
US |
1 | |
Malignant neoplasm progression, Bone loss, Pain in extremity, X-ray limb abnormal, |
||||
PEMBROLIZUMAB, CARBOPLATIN, |
||||
| 369 | 25063523 |
TN |
34 | |
Breast cancer metastatic, Malignant neoplasm progression, Haematotoxicity, |
||||
PALBOCICLIB, |
||||
| 370 | 25063616 |
US |
63 | 2 |
Malignant neoplasm progression, Off label use, Off label use, |
||||
TUCATINIB, TUCATINIB, TUCATINIB, |
||||
| 371 | 25063867 |
US |
60 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, |
||||
PALBOCICLIB, CHLORTHALIDONE, AMLODIPINE BESYLATE, LISINOPRIL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ATENOLOL, ALLOPURINOL, PREDNISONE, |
||||
| 372 | 25063887 |
DE |
50 | 1 |
Malignant neoplasm progression, Autoimmune thyroiditis, Hypokalaemia, Pneumonia staphylococcal, Neutropenia, Vascular device infection, Mucosal inflammation, Fatigue, Taste disorder, Tumour pain, |
||||
CARBOPLATIN, NIVOLUMAB, IPILIMUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, GRANISETRON, GRANISETRON HYDROCHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, APREPITANT, CIPROFLOXACIN HYDROCHLORIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, FILGRASTIM, |
||||
| 373 | 25063908 |
FR |
63 | 2 |
Enterocolitis, Disease progression, Malignant neoplasm progression, Drug ineffective, Mucosal inflammation, |
||||
AZACITIDINE, AZACITIDINE FOR, HYDROXYUREA, LENALIDOMIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, ERYTHROPOIETIN, TREOSULFAN, THIOTEPA, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, BUSULFAN, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYCLOSPORINE, ACYCLOVIR, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, RUXOLITINIB, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BUSULFAN, BUSULFAN, |
||||
| 374 | 25064143 |
US |
||
Malignant neoplasm progression, Neurological symptom, |
||||
OSIMERTINIB, |
||||
| 375 | 25064149 |
PT |
1 | |
Hyperglycaemic hyperosmolar nonketotic syndrome, Hypomagnesaemia, Hypocalcaemia, Neuropathy peripheral, Malignant neoplasm progression, Interstitial lung disease, Cell death, Asthenia, Therapy partial responder, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FUROSEMIDE, LOSARTAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ROSUVASTATIN, LORAZEPAM, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 376 | 25064196 |
BG |
75 | 1 |
Malignant neoplasm progression, Transaminases increased, |
||||
ENZALUTAMIDE, LEUPROLIDE ACETATE, DENOSUMAB, DENOSUMAB, |
||||
| 377 | 25064324 |
BG |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 378 | 25064395 |
JP |
63 | 2 |
Malignant neoplasm progression, Malaise, Colitis ischaemic, Pyrexia, Hepatic function abnormal, Enterocolitis, Palmar-plantar erythrodysaesthesia syndrome, Hypertension, Platelet count decreased, White blood cell count decreased, Pyrexia, Hepatic function abnormal, |
||||
PEMBROLIZUMAB, LENVATINIB, LENVATINIB, LENVATINIB, |
||||
| 379 | 25064480 |
RO |
32 | 2 |
Spinal cord infection, Spinal cord compression, Metastases to central nervous system, Metastases to bone, Breast cancer metastatic, Malignant neoplasm progression, Metastases to liver, |
||||
TRASTUZUMAB, |
||||
| 380 | 25064487 |
JP |
36 | 2 |
Malignant neoplasm progression, Onycholysis, Skin ulcer, |
||||
PEMBROLIZUMAB, |
||||
| 381 | 25064641 |
JP |
80 | 1 |
Malignant neoplasm progression, Off label use, |
||||
PEMBROLIZUMAB, |
||||
| 382 | 25064787 |
JP |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, TREMELIMUMAB, |
||||
| 383 | 25065140 |
US |
83 | 2 |
Lung neoplasm malignant, Breast cancer female, Malignant neoplasm progression, Off label use, |
||||
ENCORAFENIB, ENCORAFENIB, BINIMETINIB, BINIMETINIB, |
||||
| 384 | 25065148 |
KR |
65 | 1 |
Diffuse large B-cell lymphoma, Malignant neoplasm progression, Pyrexia, Disorientation, |
||||
TISAGENLECLEUCEL, |
||||
| 385 | 25065173 |
US |
75 | |
Malignant neoplasm progression, |
||||
NIVOLUMAB AND RELATLIMAB-RMBW, |
||||
| 386 | 25065339 |
JP |
86 | 1 |
Malignant neoplasm progression, Tumour compression, Feeding disorder, |
||||
PEMBROLIZUMAB, |
||||
| 387 | 25065632 |
JP |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 388 | 25056875 |
US |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 389 | 25057029 |
JP |
82 | 1 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 390 | 25057725 |
JP |
65 | 1 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 391 | 25057726 |
US |
60 | 1 |
Malignant neoplasm progression, Urinary retention, Urine flow decreased, |
||||
ENZALUTAMIDE, |
||||
| 392 | 25057818 |
JP |
55 | |
Malignant neoplasm progression, Metastases to lymph nodes, Metastases to bone, |
||||
GEFITINIB, GEFITINIB, GEFITINIB, GEFITINIB, ERLOTINIB HYDROCHLORIDE, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 393 | 25058465 |
HK |
||
Non-small cell lung cancer metastatic, Malignant neoplasm progression, Metastases to central nervous system, Nervous system disorder, Suicidal ideation, |
||||
LORLATINIB, |
||||
| 394 | 25058492 |
JP |
6 | 1 |
Subdural haematoma, Malignant neoplasm progression, Blast cell count increased, |
||||
ELRANATAMAB-BCMM, |
||||
| 395 | 25058599 |
US |
57 | |
Malignant neoplasm progression, BRAF V600E mutation positive, |
||||
OSIMERTINIB, |
||||
| 396 | 25058924 |
CN |
66 | 1 |
Malignant neoplasm progression, White blood cell count decreased, Platelet count decreased, Platelet count decreased, Platelet count decreased, Nausea, Vomiting, |
||||
OXALIPLATIN, RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, SIMVASTATIN, GLYCERIN, GLYCERIN SUPPOSITORY, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, CIMETIDINE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ASCORBIC ACID, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, |
||||
| 397 | 25059344 |
US |
2 | |
Malignant neoplasm progression, |
||||
ERIBULIN MESYLATE, |
||||
| 398 | 25059623 |
JP |
74 | 2 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 399 | 25060780 |
IN |
53 | 2 |
Malignant neoplasm progression, Product use in unapproved indication, |
||||
CAPECITABINE, |
||||
| 400 | 25060818 |
JP |
79 | 2 |
Malignant neoplasm progression, Immune-mediated enterocolitis, Drowning, Gingivitis, Motor dysfunction, Hypertension, Back pain, Malaise, Blood thyroid stimulating hormone increased, Arthralgia, Hypertension, Diarrhoea, Erythema, Hypoaesthesia, Off label use, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28